Seza Ã–zen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8561930/publications.pdf

Version: 2024-02-01

102	10,877	61687 45	38517 99
papers	citations	h-index	g-index

102	102	102	9139
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Correspondence on â€˜Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine-learning-based model to assist the diagnosis of systemic lupus erythematosusâ€™. Annals of the Rheumatic Diseases, 2023, 82, e144-e144.	0.5	5
2	Response to: â€˜Correspondence on â€˜Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trialâ€™â€™ by Satiset al. Annals of the Rheumatic Diseases, 2022, 81, e257-e257.	0.5	0
3	International Consensus for the Dosing of Corticosteroids in <scp>Childhoodâ€Onset</scp> Systemic Lupus Erythematosus With Proliferative Lupus Nephritis. Arthritis and Rheumatology, 2022, 74, 263-273.	2.9	14
4	The performances of the ILAR, ASAS, and PRINTO classification criteria in ERA patients: a comparison study. Clinical Rheumatology, 2022, 41, 1785-1792.	1.0	5
5	Polyarteritis nodosa. Current Opinion in Pediatrics, 2022, 34, 229-233.	1.0	4
6	Probiotic use in the prophylaxis of periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome: a retrospective cohort study. Rheumatology International, 2022, , 1.	1.5	7
7	The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS. Annals of the Rheumatic Diseases, 2022, 81, 601-613.	0.5	31
8	Neurologic manifestations in children with COVID-19 from a tertiary center in Turkey and literature review. European Journal of Paediatric Neurology, 2022, 37, 139-154.	0.7	15
9	Treatment of childhood-onset Takayasu arteritis: switching between anti-TNF and anti-IL-6 agents. Rheumatology, 2022, 61, 4885-4891.	0.9	4
10	The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology Points to Consider for Diagnosis and Management of Autoinflammatory Type I Interferonopathies: <scp>CANDLE</scp>/<scp>PRAAS</scp>, <scp>SAVI</scp>, and <scp>AGS</scp>. Arthritis and Rheumatology, 2022, 74, 735-751.	2.9	23
11	Familial Mediterranean Fever: How to Interpret Genetic Results? How to Treat? A Quarter of a Century After the Association with the Mefv Gene. Current Rheumatology Reports, 2022, 24, 206-212.	2.1	6
12	Human OTULIN haploinsufficiency impairs cell-intrinsic immunity to staphylococcal Î±-toxin. Science, 2022, 376, eabm6380.	6.0	25
13	The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist. Annals of the Rheumatic Diseases, 2022, 81, 907-921.	0.5	38
14	Neurologic manifestations in children with COVID-19. European Journal of Paediatric Neurology, 2022, , .	0.7	0
15	The Performances of the ACR 1997, SLICC 2012, and EULAR/ACR 2019 Classification Criteria in Pediatric Systemic Lupus Erythematosus. Journal of Rheumatology, 2021, 48, 907-914.	1.0	28
16	Performances of the â€œMS-scoreâ€•And â€œHScoreâ€•in the diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis patients. Rheumatology International, 2021, 41, 87-93.	1.5	3
17	Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach. Rheumatology, 2021, 60, 3799-3808.	0.9	29
18	Renal Vasculitis. , 2021, , 1-18.		0

#	Article	IF	Citations
19	Biological classification of childhood arthritis: roadmap to a molecular nomenclature. Nature Reviews Rheumatology, 2021, 17, 257-269.	3.5	52
20	Galectin-3: a new biomarker for differentiating periodic fever, adenitis, pharyngitis, aphthous stomatitis (PFAPA) syndrome from familial Mediterranean fever?. Rheumatology International, 2021, , 1.	1.5	2
21	Diversity in Serine/Threonine Protein Kinase-4 Deficiency and Review of the Literature. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3752-3766.e4.	2.0	13
22	Systematic review of childhood-onset polyarteritis nodosa and DADA2. Seminars in Arthritis and Rheumatism, 2021, 51, 559-564.	1.6	14
23	Hematopoietic Cell Transplantation Cures Adenosine Deaminase 2 Deficiency: Report on 30 Patients. Journal of Clinical Immunology, 2021, 41, 1633-1647.	2.0	43
24	Wind of Change in the Treatment of Childhood-Onset Takayasu Arteritis: a Systematic Review. Current Rheumatology Reports, 2021, 23, 68.	2.1	3
25	Update in familial Mediterranean fever. Current Opinion in Rheumatology, 2021, 33, 398-402.	2.0	16
26	Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa: An Openâ€Łabel, Randomized, Bayesian Noninferiority Trial. Arthritis and Rheumatology, 2021, 73, 1673-1682.	2.9	17
27	The role of vascular inflammation markers in deficiency of adenosine deaminase 2. Seminars in Arthritis and Rheumatism, 2021, 51, 839-844.	1.6	7
28	Familial Mediterranean fever-related miR-197-3p targets IL1R1 gene and modulates inflammation in monocytes and synovial fibroblasts. Scientific Reports, 2021, 11, 685.	1.6	28
29	Deubiquitination of proteasome subunits by OTULIN regulates type I IFN production. Science Advances, 2021, 7, eabi6794.	4.7	8
30	Microbiome is not linked to clinical disease severity of familial Mediterranean fever in an international cohort of children. Clinical and Experimental Rheumatology, 2021, 39, 102-108.	0.4	3
31	Inflammation-related differentially expressed common miRNAs in systemic autoinflammatory disorders patients can regulate the clinical course. Clinical and Experimental Rheumatology, 2021, 39, 109-117.	0.4	13
32	A Monogenic Disease with a Variety of Phenotypes: Deficiency of Adenosine Deaminase 2. Journal of Rheumatology, 2020, 47, 117-125.	1.0	65
33	A clinical score to guide in decision making for monogenic type I IFNopathies. Pediatric Research, 2020, 87, 745-752.	1.1	16
34	How the COVID-19 pandemic has influenced pediatric rheumatology practice: Results of a global, cross-sectional, online survey. Seminars in Arthritis and Rheumatism, 2020, 50, 1262-1268.	1.6	22
35	Kawasaki-like disease in children with COVID-19. Rheumatology International, 2020, 40, 2105-2115.	1.5	67
36	Clusters in Pediatric Rheumatic Diseases. Current Rheumatology Reports, 2020, 22, 28.	2.1	4

#	Article	IF	Citations
37	Implications of COVID-19 in pediatric rheumatology. Rheumatology International, 2020, 40, 1193-1213.	1.5	35
38	ISSAID/EMQN Best Practice Guidelines for the Genetic Diagnosis of Monogenic Autoinflammatory Diseases in the Next-Generation Sequencing Era. Clinical Chemistry, 2020, 66, 525-536.	1.5	43
39	Ancient familial Mediterranean fever mutations in human pyrin and resistance to Yersinia pestis. Nature Immunology, 2020, 21, 857-867.	7.0	90
40	Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial. Annals of the Rheumatic Diseases, 2020, 79, 1362-1369.	0.5	39
41	Choroidal vascularity index as a biomarker of systemic inflammation in childhood Polyarteritis Nodosa and adenosine deaminase-2 deficiency. Pediatric Rheumatology, 2020, 18, 29.	0.9	17
42	Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases. Journal of Clinical Investigation, 2020, 130, 1669-1682.	3.9	142
43	Measuring Vasculitis with Numbers: Outcome Scores. Current Rheumatology Reviews, 2020, 16, 21-28.	0.4	6
44	Burden of illness in hereditary periodic fevers: a multinational observational patient diary study. Clinical and Experimental Rheumatology, 2020, 38 Suppl 127, 26-34.	0.4	3
45	Deficiency of adenosine deaminase 2; special focus on central nervous system imaging. Journal of Neuroradiology, 2019, 46, 193-198.	0.6	21
46	Classification criteria for autoinflammatory recurrent fevers. Annals of the Rheumatic Diseases, 2019, 78, 1025-1032.	0.5	300
47	Cancer incidence in familial Mediterranean fever patients: a retrospective analysis from central Anatolia. Rheumatology International, 2019, 39, 1045-1051.	1.5	4
48	European consensus-based recommendations for the diagnosis and treatment of rare paediatric vasculitides â€“ the SHARE initiative. Rheumatology, 2019, 58, 656-671.	0.9	77
49	Systemic onset juvenile idiopathic arthritis: a single center experience. Turkish Journal of Pediatrics, 2019, 61, 852.	0.3	10
50	Familial Mediterranean fever patients homozygous for E148Q variant may have milder disease. International Journal of Rheumatic Diseases, 2018, 21, 1857-1862.	0.9	24
51	JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. Journal of Clinical Investigation, 2018, 128, 3041-3052.	3.9	387
52	Towards a new set of classification criteria for PFAPA syndrome. Pediatric Rheumatology, 2018, 16, 60.	0.9	32
53	Pediatric forms of vasculitis. Best Practice and Research in Clinical Rheumatology, 2018, 32, 137-147.	1.4	11
54	Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. New England Journal of Medicine, 2018, 378, 1908-1919.	13.9	327

#	Article	IF	Citations
55	Vasculitis: Decade in Review. Current Rheumatology Reviews, 2018, 15, 14-22.	0.4	11
56	A patient heterozygous for r92q mutation with periodic fever and aphthous stomatitis, pharyngitis, and adenitis (pfapa) syndrome-like phenotype. Turkish Journal of Pediatrics, 2018, 60, 726.	0.3	5
57	Development of the autoinflammatory disease damage index (ADDI). Annals of the Rheumatic Diseases, 2017, 76, 821-830.	0.5	68
58	EULAR/PReS standards and recommendations for the transitional care of young people with juvenile-onset rheumatic diseases. Annals of the Rheumatic Diseases, 2017, 76, 639-646.	0.5	157
59	Comparing polyarteritis nodosa in children and adults: a single center study. International Journal of Rheumatic Diseases, 2017, 20, 1016-1022.	0.9	30
60	Colchicine resistance and intolerance in familial mediterranean fever: Definition, causes, and alternative treatments. Seminars in Arthritis and Rheumatism, 2017, 47, 115-120.	1.6	108
61	Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS). Annals of the Rheumatic Diseases, 2017, 76, 942-947.	0.5	175
62	Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications. Annals of the Rheumatic Diseases, 2017, 76, 906-913.	0.5	123
63	International Retrospective Chart Review of Treatment Patterns in Severe Familial Mediterranean Fever, Tumor Necrosis Factor Receptorâ€“Associated Periodic Syndrome, and Mevalonate Kinase Deficiency/Hyperimmunoglobulinemia D Syndrome. Arthritis Care and Research, 2017, 69, 578-586.	1.5	75
64	Tocilizumab treatment in childhood Takayasu arteritis: Case series of four patients and systematic review of the literature. Seminars in Arthritis and Rheumatism, 2017, 46, 529-535.	1.6	42
65	Discontinuing colchicine in symptomatic carriers for MEFV (Mediterranean FeVer) variants. Clinical Rheumatology, 2017, 36, 421-425.	1.0	33
66	Familial Mediterranean Fever: Recent Developments in Pathogenesis and New Recommendations for Management. Frontiers in Immunology, 2017, 8, 253.	2.2	135
67	A web-based collection of genotype-phenotype associations in hereditary recurrent fevers from the Eurofever registry. Orphanet Journal of Rare Diseases, 2017, 12, 167.	1.2	52
68	Comparison of patients with familial Mediterranean fever accompanied with sacroiliitis and patients with juvenile spondyloarthropathy. Clinical and Experimental Rheumatology, 2017, 35 Suppl 108, 124-127.	0.4	7
69	Alteration of the microRNA expression profile in familial Mediterranean fever patients. Clinical and Experimental Rheumatology, 2017, 35 Suppl 108, 90-94.	0.4	13
70	Familial Mediterranean fever: current perspectives. Journal of Inflammation Research, 2016, 9, 13.	1.6	82
71	Biallelic hypomorphic mutations in a linear deubiquitinase define otulipenia, an early-onset autoinflammatory disease. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 10127-10132.	3.3	206
72	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis and Rheumatology, 2016, 68, 566-576.	2.9	427

#	Article	IF	Citations
73	Periodic Fever, Aphthosis, Pharyngitis, and Adenitis Syndrome: Analysis of Patients From Two Geographic Areas. Arthritis Care and Research, 2016, 68, 1859-1865.	1.5	41
74	Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. RMD Open, 2016, 2, e000161.	1.8	57
75	Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. Nature Genetics, 2016, 48, 67-73.	9.4	513
76	EULAR recommendations for the management of familial Mediterranean fever. Annals of the Rheumatic Diseases, 2016, 75, 644-651.	0.5	393
77	Genetic and clinical features of cryopyrin-associated periodic syndromes in Turkish children. Clinical and Experimental Rheumatology, 2016, 34, S115-S120.	0.4	12
78	Vasculitis in children. Nephrology Dialysis Transplantation, 2015, 30 Suppl 1, i94-103.	0.4	24
79	A Case Series of Adenosine Deaminase 2-deficient Patients Emphasizing Treatment and Genotype-phenotype Correlations. Journal of Rheumatology, 2015, 42, 1532-1534.	1.0	80
80	HLA-DRB1*11and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15970-15975.	3.3	139
81	Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. Annals of the Rheumatic Diseases, 2015, 74, 799-805.	0.5	215
82	Evidence-based recommendations for genetic diagnosis of familial Mediterranean fever. Annals of the Rheumatic Diseases, 2015, 74, 635-641.	0.5	145
83	The myths we believed in familial Mediterranean fever: what have we learned in the past years?. Seminars in Immunopathology, 2015, 37, 363-369.	2.8	37
84	Validation of the Auto-Inflammatory Diseases Activity Index (AIDAI) for hereditary recurrent fever syndromes. Annals of the Rheumatic Diseases, 2014, 73, 2168-2173.	0.5	120
85	A clinical guide to autoinflammatory diseases: familial Mediterranean fever and next-of-kin. Nature Reviews Rheumatology, 2014, 10, 135-147.	3.5	195
86	Clinical Features, Treatment, and Outcome of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A Multinational, Multicenter Study of 362 Patients. Arthritis and Rheumatology, 2014, 66, 3160-3169.	2.9	322
87	Early-Onset Stroke and Vasculopathy Associated with Mutations in ADA2. New England Journal of Medicine, 2014, 370, 911-920.	13.9	687
88	Clinical features of childhood granulomatosis with polyangiitis (wegenerâ€™s granulomatosis). Pediatric Rheumatology, 2014, 12, 18.	0.9	85
89	Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Annals of the Rheumatic Diseases, 2013, 72, 678-685.	0.5	350
90	Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS). Annals of the Rheumatic Diseases, 2013, 72, 1628-1633.	0.5	123

#	Article	IF	Citations
91	Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis. New England Journal of Medicine, 2012, 367, 2396-2406.	13.9	588
92	Renal amyloidosis in children. Pediatric Nephrology, 2011, 26, 1215-1227.	0.9	67
93	A preliminary score for the assessment of disease activity in hereditary recurrent fevers: results from the AIDAI (Auto-Inflammatory Diseases Activity Index) Consensus Conference. Annals of the Rheumatic Diseases, 2011, 70, 309-314.	0.5	70
94	Anti-Interleukin 1 Treatment for Patients with Familial Mediterranean Fever Resistant to Colchicine: Table 1.. Journal of Rheumatology, 2011, 38, 516-518.	1.0	132
95	EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation. Annals of the Rheumatic Diseases, 2010, 69, 790-797.	0.5	187
96	EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Annals of the Rheumatic Diseases, 2010, 69, 798-806.	0.5	1,073
97	A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology, 2009, 48, 395-398.	0.9	374
98	Takayasu arteritis in children. Journal of Rheumatology, 2008, 35, 913-9.	1.0	89
99	Country as the primary risk factor for renal amyloidosis in familial mediterranean fever. Arthritis and Rheumatism, 2007, 56, 1706-1712.	6.7	243
100	Takayasu Arteritis in Children: Preliminary Experience with Cyclophosphamide Induction and Corticosteroids Followed by Methotrexate. Journal of Pediatrics, 2007, 150, 72-76.	0.9	100
101	Juvenile polyarteritis: Results of a multicenter survey of 110 children. Journal of Pediatrics, 2004, 145, 517-522.	0.9	196
102	Mutation frequency of Familial Mediterranean Fever and evidence for a high carrier rate in the Turkish population. European Journal of Human Genetics, 2001, 9, 553-555.	1.4	273